Previous close | 7.60 |
Open | 7.60 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 7.60 - 7.60 |
52-week range | 7.60 - 7.60 |
Volume | |
Avg. volume | N/A |
Market cap | 137.495M |
Beta (5Y monthly) | 1.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.33 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
DGAP-News: BRAIN Biotech AG / Key word(s): Miscellaneous04.04.2022 / 10:40 The issuer is solely responsible for the content of this announcement.Successful Genome Editing in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC) Major milestone achieved: genome-editing in mammalian cell lines Potential to target very large addressable markets BEC, BMC well suited for different application fieldsZwingenberg, Germany, April, 4th 2022 - BRAIN Biotech AG has achieved a major mil
BRAIN Biotech AG / Key word(s): MiscellaneousBRAIN Biotech AG: Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC) 04-Apr-2022 / 10:31 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas (B
DGAP-News: BRAIN Biotech AG / Key word(s): AGM/EGM09.03.2022 / 16:00 The issuer is solely responsible for the content of this announcement.Resolutions of the Annual General Meeting for the Fiscal Year 2020/2021 of BRAIN Biotech AG Executive Board and Supervisory Board discharged by a large majority Shareholder majority approves capital reserve advance resolutions Positive outlook for the new fiscal yearZwingenberg, Germany, 9 March 2022 - At today's Annual General Meeting of BRAIN Biotech AG, th